Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937766 · ClinicalTrials.gov registry record · Phase 3
Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT02937766 is a Phase 3 study that was terminated before completion, run by AMAG Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT02937766, a Phase 3 study, was terminated before completion, sponsored by AMAG Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena®
Interventions
- DRUG Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-10-07 |
| Est. Completion | 2017-03-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02937766
The ClinicalTrials.gov registry entry for NCT02937766 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is the first listed.
NCT02937766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02937766 about?
NCT02937766 is a clinical study titled "Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women". To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena®
What is the current status of trial NCT02937766?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2016-10-07. Estimated completion is 2017-03-27.
What interventions are being tested in trial NCT02937766?
The interventions under investigation include: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) (DRUG).
Who is sponsoring clinical trial NCT02937766?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.